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Value in Health Regional IssuesIt is our pleasure to introduce this issue of Value in Health Regional
Issues (ViHRI), in this case focusing on Latin America. It is now the
eighth issue in our 3 years of existence, and the third looking at
Latin America. Our journal is steadily growing, with articles of
increasing diversity and rigor [1].
Our mission is challenging: to encourage and enhance the
science of health economic and outcomes research and its use in
supporting health care decisions in Asia, Latin America, Central
and Eastern Europe, and Africa. To better reach our goals, we are
applying to MEDLINE and are optimistic about being included
in 2015. If we succeed, the journal will be indexed from its birth
in 2012, and our visibility and impact will be “boosted.” Starting
in 2015, the Value in Health Regional Issues Excellent Article Award
will be announced and given for the best article published each
year.
While we await MEDLINE indexing and the eventual impact
factor as a widespread, though imperfect metric for a scientiﬁc
journal [2], other metrics reﬂect our journal’s increasing disse-
mination. Total ViHRI article downloads from the ISPOR Web site
have steadily increased from 1,280 in 2012 to 24,113 through the
ﬁrst 6 months of 2014. In the case of ViHRI Latin America, we had
1,065 in 2012, 20,382 in 2013, and 5,791 through the ﬁrst 6 months
of 2014.
From 2012 to date, we have received more than a hundred
article submissions to ViHRI Latin America. Colombia (n ¼ 23),
Brazil (n ¼ 21), Mexico (n ¼ 16), Chile (n ¼ 10), and Argentina (n ¼
9) are the top countries sending their scientiﬁc output, as well as
United States (n ¼ 12) though all the articles had at least one
author from Latin America and the study has to be about a
regional topic or population. Although two thirds of the submis-
sions are in English, we encourage Spanish and Portuguese
submissions to reduce barriers to the publication of local good
quality research. Almost half the submissions are economic
evaluations; other frequent study topics are patient-reported
outcomes, health policy analyses, conceptual articles, and com-
parative effectiveness. As of October 2014, ViHRI Latin America
has 7 of the 25 most cited ViHRI articles overall [3].
Our present issue builds on the previous ones [4], and is an
adequate reﬂection of our scope, in terms of both study and
research topics and geographic diversity, and it also mirrors
current priority issues in health and disease burden [5]. There
are several economic evaluations focusing on older and newer
health technologies for noncommunicable diseases. These cover
selected statins in Brazil and Colombia [6], biologics for psoriasis
in Brazil [7] and Uruguay [8], as well as studies on diabetes,
asthma, osteoarthritis, drug administration systems in intensivest: The authors have indicated that they have no
ial support: The authors have no other ﬁnancial rcare, and costs of pesticide intoxications. Interesting and timely
health policy and conceptual articles describe the process of
updating the Mexican Health Care Formulary and Supply Catalog
Cuadro Básico [9]; reﬂect on the relation of health, socioeconomic
status, and migration [10]; provide guidance on adapting global
pharmacoeconomic models [11]; and debate a controversial issue
about doctor supply [12].
We hope you enjoy the issue. It should facilitate and con-
tribute to evidence-based health policy and decision making in
our region. Though signiﬁcant heterogeneity still remains–as
shown in a recent publication about national health beneﬁt plans
[13]–Latin America is increasingly using evidence/based policy to
improve population health in an efﬁcient and equitable way.Acknowledgments
We thank Maria Cook and Jerusha Harvey from ISPOR for their
support and review of the editorial and Terry Materese from
Elsevier for providing insight about journal metrics.
Federico Augustovski, MD, MSc, PhD
Faculty of Medicine, School of Public Health, University of Buenos
Aires, Buenos Aires, Argentina
Marcos Bossi Ferraz, MD, PhD
São Paulo Center for Health Economics (GRIDES), São Paulo, Brazil
Department of Medicine, Sao Paulo School of Medicine, Federal
University of São Paulo, SãoPaulo, Brazil
J. Jaime Caro, MDCM, FRCPC, FACP
Evidera, Lexington, MA, USA
Faculty of Medicine, McGill University, Montreal, QC, CanadaVictor Zárate, MD, MSc
Faculty of Medicine, Los Andes University, Santiago, Chile
2212-1099/$36.00 – see front matter Copyright & 2014,
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR). Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.vhri.2014.10.002conﬂicts of interest with regard to the content of this article.
elationships to disclose.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 5 C ( 2 0 1 4 ) 7 3 – 7 474R E F E R E N C E S[1] Yang BM, Lee K, Guo J. A year of signiﬁcant progress for Value in Health
Regional Issues. Value Health Regional 2014;3C:172–3.
[2] Bornmann L, Marx W, Gasparyan AY, Kitas GD. Diversity, value and
limitations of the journal impact factor and alternative metrics.
Rheumatol Int 2012;32:1861–7.
[3] Most cited Value in Health Regional Issues articles. Available from: http://
www.journals.elsevier.com/value-in-health-regional-issues/
most-cited-articles/. [Accessed October 4, 2014].
[4] Augustovski F, Caro JJ, Zárate Barahona V, Bosi Ferraz M. Introducing
the new Value in Health Regional Issues journal: the Latin America region
edition. Available from: http://www.ispor.org/ValueInHealth/Show-
ValueInHealth.aspx?issue=722CCE35-54A6-4927-84A2-F538E53129D3.
[Accessed October 6, 2014].
[5] Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs)
for 291 diseases and injuries in 21 regions, 1990–2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet
2012;380:2197–223.
[6] Mould-Quevedo JF, Gutierrez Ardilia MV, Ordoñez JE, Vargas Zea N.
Cost-effectiveness analysis of atorvastatin versus rosuvastatin in
primary and secondary cardiovascular prevention populations in Brazil
and Colombia. Value Health Regional 2014;5C:48–57.[7] Salgado Riveros B, Klarmann Zeigerlmann P, Correr CJ. Cost-
effectiveness of biologic agents in the treatment of moderate to severe
psoriasis: a Brazilian Public Health Service (SUS) perspective. Value
Health Regional 2014;5C:65–72.
[8] Gonzalez-Vacarezza N, Gehling Bertoldi E, Deminco A, Martinez Asuaga
M. Análisis costo-utilidad del uso de adalimumab, etanercept e
inﬂiximab para el tratamiento de la artritis psoriásica en Uruguay
[Spanish]. Value Health Regional 2014;5C:58–64.
[9] Rizo Rios P, Gonzalez Rivera A, Rivas Oropeza I, Campos Ramirez O. The
update of the health care formulary and supply catalog in the context
of the health technology assessment. Value Health Regional
2014;5C:29–34.
[10] Cabieses B. La compleja relación entre posición socioeconómica,
estatus migratorio y resultados de salud en Chile: discusión crítica
de la evidencia cientíﬁca [Spanish]. Value Health Regional
2014;5C:1–6.
[11] Mullins D, Onwudiwe NC, Tannus G, et al. Guidance document: global
pharmacoeconomic model adaption strategies. Value Health Regional
2014;5C:7–13.
[12] Westphalen AC, Stefani SD. More doctors: thoughts about a
controversial healthcare policy. Value Health Regional 2014;5C:73–5.
[13] Health beneﬁt plans in Latin America: a regional comparison. In:
Giedion U, Bitrán R, Tristao I,eds. Inter-American Development Bank
Social Protection and Health Division. Washington, DC: Inter American
Development Bank, 2014.
